MannKind | MNKD - Ebit


MannKind reported $-68.23M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
Adma Biologics USD 59.23M 3.52M Mar/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Insmed USD -101.31M 98.97M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -31.88M 19.79M Mar/2026
MannKind USD -68.23M 8.76M Jun/2026
Merck USD 840M 2.72B Jun/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD 20.94M 100.32M Dec/2025
Novo Nordisk DKK 5.25B 60.42B Jun/2026
Pfizer USD -180M 5.16B Jun/2026
Sanofi EUR 1.12B 811M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026